Efficacy of alternate day dosing of atorvastatin

Central European Journal of Medicine

Volumn 3, Issue 2, 2008, Pages 163-166

  Aghasadeghi, Kamran ^a   Zare, Didar ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Atorvastatin; Cholesterol; Dosing; Lipoprotein

Indexed keywords

ATORVASTATIN; CHOLESTEROL; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 41949138374     PISSN: 18951058     EISSN: 16443640     Source Type: Journal    
DOI: 10.2478/s11536-007-0063-x     Document Type: Article

References (14)

1. Genest J.J., McNamard J.R., Salem D.N., Schaefer E.J., Prevalence of risk factors in men with premature coronary artery disease, Am. J. Cardiol., 1991, 67, 1185-1189
2. Lacoste L., Lam J.Y.T., Hung J., Letchacovski G., Solymoss C.B., Waters D., Hyperlipidemia and coronary disease correction of the increased thrombogenic potential with cholesterol reduction, Circulation, 1995, 92, 3128-3177
3. Castelli M.P., Garrison R.J., Wilson P.W., Abbott R.D., Kalousdian S., Kannel W.B., Incidence of coronary heart disease and lipoprotein cholesterol level. The Framingham study, JAMA, 1986, 256, 2835-2838
4. Grundy S.M., Balady G.J., Criqui M.H., Fletcher G., Greenland P., Hiratzka L.F., et al., Primary prevention of coronary heart disease: guidance from Framingham, Circulation, 1998, 97, 1876-1887
5. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., Bernini F., New insight into the pharmacodynamic and pharmacokinetic properties of statin, Pharmacol. Ther., 1999, 84, 413-428
6. Robert W.M., Thomas B.P., Drug therapy for hypercholesterolemia and dyslipidemia. In: Goodmann and Gillmann's Pharmacologic basis of therapeutics. 10th International Edition 2001.
7. Davidson M., McKenny J., Stein E.A., Comparison of one year efficacy and safety of etorvastatin versus lovastatin in primary hypercholesterolemia, Am. J. Cardiol., 1997, 79, 1475-1481
8. Gibson B.M., Bron N.J., Richens A., Hounslow N.J., Sedman A.J., Whitfield L.R., Effect of age and gender pharmacokinetics of atorvastatin in humans, J. Clin. Pharmacol., 1996, 36, 242-246
9. National cholesterol education program expert panel. Executive summary of third report of the national cholesteroleducation program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adult, JAMA, 2001, 285, 2486-2497
10. Treasure C.B., Klein J.L., Weintraub W.S., Talley J.D., Stillabower M.E., Kosinski A.S., et al., Beneficial effects of cholesterol lowering therapy on coronary endothelium in patients with coronary artery disease, N. Eng. J. Med., 1995, 332, 481-487
11. Brown B.G., Zhao X.Q., Sacco D.E., Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease, Circulation, 1993, 87, 1781-1791
12. Corsini A., Pazzucconi F., Arnaboldi L., Pfister P., Fumagalli R., Paoletti R., et al., Direct effect of statins on the vascular wall, J. Cardiovasc. Pharmacol., 1998, 31, 773-778
13. Tandon V., Bano G., Khajuria V., Parihar A., Gupta S., Pleiotropic effects of statins, Indian J. Pharmacol., 2005, 37, 77-85
14. Werba P.J., Tremoli E., Massironi P., Camera M., Cannata A., Alamanni F., et al., Statins in coronary bypass surgery: rationale and clinical use, Ann. Thorac. Surg., 2003, 76, 2132-2140